Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 12/2023

23.06.2023 | Original Paper

Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya

verfasst von: Nicholas Musinguzi, Kenneth Ngure, Elizabeth A. Bukusi, Nelly R. Mugo, Jared M. Baeten, Peter L. Anderson, Jessica E. Haberer

Erschienen in: AIDS and Behavior | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Understanding PrEP adherence is key in the formulation of HIV prevention strategies; however, measurement of adherence can be challenging. We compared multiple adherence measures in a two-year study of young Kenyan women at high risk of HIV acquisition. Among 289 participants, concordance between electronic adherence monitoring (EAM) and tenofovir diphosphate (TFV-DP) in dried blood spots ranged from 57 to 72% depending on selected thresholds. Using area under the receiver operating curve, discrimination of quantifiable TFV-DP was high at 0.85 with EAM and low at 0.49–0.54 for multiple self-reported measures. Correlation between EAM and self-reported measures was low (r < 0.11) although correlation within self-reported measures was moderate (r > 0.69). These findings indicate that both TFV-DP and EAM are useful PrEP adherence tools. Adherence would benefit from better availability of less expensive versions of both measurement tools. Additionally, further research on TFV-DP thresholds is needed to inform interpretation and use in understanding PrEP adherence in this population.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
UNAIDS.org. Global HIV & AIDS statistics - Fact sheet. 2020.
2.
Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11:10–7.CrossRefPubMedPubMedCentral
3.
4.
Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23:e25463.CrossRefPubMedPubMedCentral
5.
Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(Suppl 4):e25298.CrossRefPubMedPubMedCentral
6.
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure Prophylaxis for HIV infection among african women. N Engl J Med. 2012;367:411–22.CrossRefPubMedPubMedCentral
7.
Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, et al. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022;25:e25962.CrossRefPubMedPubMedCentral
8.
Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18:e1003670.CrossRefPubMedPubMedCentral
9.
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among african women. N Engl J Med. 2015;372:509–18.CrossRefPubMedPubMedCentral
10.
Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, et al. A translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis against HIV in Men and Women using Tenofovir Disoproxil Fumarate with or without Emtricitabine. J Infect Dis. 2016;214:55–64.CrossRefPubMedPubMedCentral
11.
Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):149–55.CrossRef
12.
Benitez AE, Musinguzi N, Bangsberg DR, Bwana MB, Muzoora C, Hunt PW, et al. Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda. J Int AIDS Soc. 2020;23:e25467.CrossRefPubMedPubMedCentral
13.
Musinguzi N, Mocello RA, Boum Y, Hunt PW, Martin JN, Haberer JE, et al. Duration of viral suppression and risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. AIDS Behav. 2017;21:1735–40.CrossRefPubMedPubMedCentral
14.
Musinguzi N, Muganzi CD, Boum Y 2nd, Ronald A, Marzinke MA, Hendrix CW, et al. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS. 2016;30:1121–9.CrossRefPubMed
15.
Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22:1165–73.CrossRefPubMed
16.
Elbireer AM, Jackson JB, Sendagire H, Opio A, Bagenda D, Amukele TK. The good, the bad, and the unknown: quality of clinical laboratories in Kampala, Uganda. PLoS ONE. 2013;8:e64661.CrossRefPubMedPubMedCentral
17.
Schroeder LF, Amukele T. Medical laboratories in sub-saharan Africa that meet international quality standards. Am J Clin Pathol. 2014;141:791–5.CrossRefPubMed
18.
Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384–90.CrossRefPubMedPubMedCentral
19.
Pyra M, Anderson P, Haberer JE, Heffron R, Celum C, Asiimwe S, et al. Tenofovir-Diphosphate as a marker of HIV Pre-exposure Prophylaxis Use among East African Men and Women. Front Pharmacol. 2019;10:401.CrossRefPubMedPubMedCentral
20.
Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother 2018,62.
21.
Ibrahim ME, Castillo-Mancilla JR, Yager J, Brooks KM, Bushman L, Saba L, et al. Individualized adherence benchmarks for HIV Pre-Exposure Prophylaxis. AIDS Res Hum Retroviruses. 2021;37:421–8.CrossRefPubMedPubMedCentral
22.
Mboup A, Béhanzin L, Guédou F, Giguère K, Geraldo N, Zannou DM, et al. Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin. Med (Baltim). 2020;99:e20063.CrossRef
23.
Haberer JE, Musinguzi N, Tsai AC, Boum Y 2nd, Bwana BM, Muzoora C, et al. Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. AIDS. 2017;31:169–71.CrossRefPubMed
24.
Haberer JE, Bukusi EA, Mugo NR, Pyra M, Kiptinness C, Oware K, et al. Effect of SMS reminders on PrEP adherence in young kenyan women (MPYA study): a randomised controlled trial. Lancet HIV. 2021;8:e130–7.CrossRefPubMedPubMedCentral
25.
Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390–401.CrossRefPubMedPubMedCentral
26.
Delahunty T, Bushman L, Robbins B, Fletcher CV. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1907–14.CrossRefPubMedPubMedCentral
27.
Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a New Three-Item Self-Report measure for Medication Adherence. AIDS Behav. 2016;20:2700–8.CrossRefPubMedPubMedCentral
28.
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.CrossRefPubMedPubMedCentral
29.
Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16–20.CrossRefPubMedPubMedCentral
30.
Tape TG. Interpretation of diagnostic tests. Ann Intern Med. 2001;135:72.CrossRef
31.
Kenneth K, Mugwanya PLA. The Women TDF-FTC Benchmark Study. Kenya Medical Research Institute - Partners in Health Research and Development Thika, Kenya: National Institute of Allergy and Infectious Diseases (NIAID); 2022.
32.
Blumenthal J, Pasipanodya EC, Jain S, Sun S, Ellorin E, Morris S, et al. Comparing Self-Report Pre-Exposure Prophylaxis adherence questions to pharmacologic measures of recent and cumulative pre-exposure Prophylaxis exposure. Front Pharmacol. 2019;10:721.CrossRefPubMedPubMedCentral
33.
Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, et al. Comparison of measures of adherence to human immunodeficiency Virus Preexposure Prophylaxis among adolescent and young men who have sex with men in the United States. Clin Infect Dis. 2018;66:213–9.CrossRefPubMed
34.
Musinguzi N, Muwonge T, Ngure K, Katabira E, Mugo N, Burns BFO, et al. Comparison of short messaging service self-reported adherence with other adherence measures in a demonstration project of HIV preexposure prophylaxis in Kenya and Uganda. AIDS. 2018;32:2237–45.CrossRefPubMed
35.
WHO. WHO recommends long-acting cabotegravir for HIV prevention. In; 2022.
36.
UN.org. Gamechanger HIV injection rolls out in South Africa and Brazil. In; 2022.
37.
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a Vaginal Ring containing dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016;375:2121–32.CrossRefPubMedPubMedCentral
Metadaten
Titel
Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya
verfasst von
Nicholas Musinguzi
Kenneth Ngure
Elizabeth A. Bukusi
Nelly R. Mugo
Jared M. Baeten
Peter L. Anderson
Jessica E. Haberer
Publikationsdatum
23.06.2023
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 12/2023
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-023-04111-2

Weitere Artikel der Ausgabe 12/2023

AIDS and Behavior 12/2023 Zur Ausgabe

Original Paper

Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis

Original Paper

Adherence to Antiretrovirals and HIV Viral Suppression Under COVID-19 Pandemic Interruption – Findings from a Randomized Clinical Trial Using Ingestible Sensors to Monitor Adherence

Original Paper

National Surveillance of Home-Based HIV Testing Among Australian Gay and Bisexual Men, 2018–2020: Uptake After Commercial Availability of HIV Self-Tests

Original Paper

The Importance of the Individual in PrEP Uptake: Multilevel Correlates of PrEP Uptake Among Adolescent Girls and Young Women in Tshwane, South Africa

Original Paper

Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda

Original Paper

Acceptability and Effectiveness of a One-Hour Healthcare Provider Intervention Integrating HIV Pre-Exposure Prophylaxis and Cultural Competence Training

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise